首页 | 本学科首页   官方微博 | 高级检索  
检索        

EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义
引用本文:王海燕,彭李博,王建军,文娟娟,石群立,王璇,王建东.EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义[J].临床肿瘤学杂志,2014,19(11):996-999.
作者姓名:王海燕  彭李博  王建军  文娟娟  石群立  王璇  王建东
作者单位:南京军区南京总医院病理科
摘    要:目的 探讨受体酪氨酸激酶EphA1在卵巢浆液性腺癌中的表达水平并分析其与临床病理特征的关系,为筛选可用于卵巢浆液性腺癌的诊断和预后指标提供依据。方法 采用免疫细胞化学法检测不同人浆液性卵巢癌细胞系HO8910、SKOV3和A2780细胞中EphA1的表达情况。采用免疫组化染色检测EphA1在76例卵巢浆液性腺癌组织中的表达情况,将结果分为:低表达(≤5分)和高表达(>5分);分析EphA1表达与临床病理特征的关系。结果 EphA1在HO8910、SKOV3细胞中呈阴性表达,而在A2780细胞中呈弱阳性表达。76例卵巢浆液性腺癌组织中,EphA1高表达33例(43.4%),低表达43例(56.6%)。EphA1表达与WHO分级、MDACC分级有关(P<0.05),而与临床分期、转移情况、发生部位、肿瘤直径及年龄均无关(P>0.05)。EphA1高表达者的中位总生存期为71.0个月,高于EphA1低表达者的31.0个月,差异有统计学意义(P<0.05)。结论 EphA1蛋白在卵巢浆液性腺癌中低表达,其表达与组织学分级和预后均有关,有可能成为卵巢浆液性腺癌辅助诊断及临床预后的新指标。

关 键 词:EphA1  卵巢浆液性腺癌  卵巢癌细胞系  预后
收稿时间:2014-05-28
修稿时间:2014-07-24

Expression of EphA1 protein in ovarian serous adenocarcinoma and its clinical significance
WANG Haiyan,PENG Libo,WANG Jianjun,WEN Juanjuan,SHI Qunli,WANG Xuan,WANG Jiandong.Expression of EphA1 protein in ovarian serous adenocarcinoma and its clinical significance[J].Chinese Clinical Oncology,2014,19(11):996-999.
Authors:WANG Haiyan  PENG Libo  WANG Jianjun  WEN Juanjuan  SHI Qunli  WANG Xuan  WANG Jiandong
Institution:Department of Pathology, Nanjing General Hospital of Nanjing Military Command
Abstract:Objective To explore the expression level of EphA1 in ovarian serous adenocarcinoma and analyze its correlation with clinicopathological characteristics, as to provide reference for screening a new indicator in ovarian serous adenoeareinoma for diag- nosis and prognosis. Methods The immunocytochemical method was employed to measure the expression of EphA1 in human ovarian cancer cell lines HO8910, SKOV3 and A2780 cells. The protein expression level of EphA1 in 76 ovarian serous adenocarcinoma tissues was detected by immunohistochemical staining. The results were divided into low-level expression( ~〈 5) group and high-level expression group(〉5) according to the immunohistoehemical staining counting method. The relationships between the expression of EphA1 and clinieopathological characteristics were investigated. Results The expression of EphA1 protein was negative in HO8910 and SKOV3 cells but weakly positive in A2780 cell. Out of 76 tissue samples of ovarian serous adenocarcinoma, there were 33 cases( 43.4% ) with high-level expression and 43 cases (56. 6% ) with low-level expression, respectively. The expression of EphA1 protein was related with WHO and MDACC grading(P〈0. 05), but unrelated with clinical staging, metastasis, tumor location, tumor diameter and age (P〉0. 05). The median overall survival of high-level expression group was 71.0 months, higher than 31.0 months of low-level expression group with significant difference (P〈0. 05). Conclusion Expression of EphA1 protein in ovarian serous adenocarcinoma is down-regu- lated, and is related with high histological grade and poor prognosis. EphA1 protein may be a new index of diagnosis and clinical prog- nosis in ovarian serous ad
Keywords:EphA1  Ovarian serous adenocarcinoma  Ovarian cancer cell lines  Prognosis
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号